Lauffenburger Julie C, Gagne Joshua J, Song Zirui, Brill Gregory, Choudhry Niteesh K
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Department of Medicine, Center for Healthcare Delivery Sciences, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
BMJ Open. 2016 Aug 4;6(8):e010958. doi: 10.1136/bmjopen-2015-010958.
To explore the association between unexpected potentially disruptive life events in a patient or family member that may challenge an individual's ability to take medications as prescribed and the discontinuation of evidence-based medications for common, chronic conditions. Understanding the relationship between medication adherence and life stressors, especially those that can be identified using administrative data, may help identify patients at risk of non-adherence.
Observational self-controlled case-crossover design.
Individuals in a nationally representative US commercial health insurance database.
Adult individuals who initiated an oral hypoglycaemic, antihypertensive and/or statin and subsequently stopped the medication for ≥90 days.
Potentially disruptive life events among patients and their family members measured in the 30 days just before the medication was discontinued ('hazard period') compared with the 30 days before this period ('control period'). These events included personal injury, hospitalisation, emergency room visits, changes in insurance coverage, acute stress or acute anxiety.
Among the 326 519 patients meeting study criteria who discontinued their chronic disease medications, 88 896 (27.2%) experienced at least one potentially disruptive life event. Newly experiencing an injury (OR: 1.26, 95% CI 1.12 to 1.42), an emergency room visit (OR: 1.19, 95% CI 1.13 to 1.26) and acute stress (OR: 1.19, 95% CI 1.08 to 1.31) were associated with discontinuation. Life events among patients' family members did not appear to be associated with medication discontinuation or occurred less frequently just prior to discontinuation.
Potentially disruptive life events among individuals identified using routinely collected claims data are associated with discontinuation of chronic disease medications. Awareness of these events may help providers or payers identify patients at risk of non-adherence to maximise patient outcomes.
探讨患者或其家庭成员中意外发生的、可能干扰治疗的生活事件(这些事件可能会挑战个体按医嘱服药的能力)与常见慢性病循证药物停药之间的关联。了解药物依从性与生活压力源之间的关系,尤其是那些可通过管理数据识别的压力源,可能有助于识别存在不依从风险的患者。
观察性自我对照病例交叉设计。
来自具有全国代表性的美国商业健康保险数据库中的个体。
开始使用口服降糖药、抗高血压药和/或他汀类药物,随后停药≥90天的成年个体。
在停药前30天(“危险期”)与该时期前30天(“对照期”)相比,测量患者及其家庭成员中可能干扰治疗的生活事件。这些事件包括人身伤害、住院、急诊就诊次数、保险覆盖范围变化、急性应激或急性焦虑。
在符合研究标准的326519例停用慢性病药物的患者中,88896例(27.2%)经历了至少一次可能干扰治疗的生活事件。新发生的伤害(比值比:1.26,95%置信区间1.12至1.42)、急诊就诊(比值比:1.19,95%置信区间1.13至1.26)和急性应激(比值比:1.19,95%置信区间1.08至1.31)与停药相关。患者家庭成员的生活事件似乎与药物停药无关,或在停药前发生频率较低。
使用常规收集的索赔数据识别出的个体中,可能干扰治疗的生活事件与慢性病药物停药有关。了解这些事件可能有助于医疗服务提供者或支付方识别存在不依从风险 的患者,以实现最佳的患者治疗效果。